Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease is a topic covered in the Evidence-Based Medicine Guidelines.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central